MAY 23, 2018 1:10 AM PDT

Potential Treatment for Triple-Negative Breast Cancer

WRITTEN BY: Nouran Amin


Recent research published in the Journal of Clinical Investigation examined the drug Dacogen (decitabine), which was observed to target the growth of cancer and was effective in treating tumors resistant to chemotherapy. The Food and Drug Administration has approved decitabine for treating bone marrow and blood cancers

“Patients whose tumor does not respond well to chemotherapy are known to be at significantly increased risk of recurrent breast cancer and death,” expalins Judy Boughey, MD, a general surgeon at the Cancer Center at the Mayo Clinic in Rochester, Minnesota. “Therefore, our focus is to identify new treatment options for these patients.”

 

 

Breast cancer is responsible for 30 percent of new cancer diagnoses in women in the United States each year. About 1 in 8 women will be diagnosed with invasive breast cancer at some point in their lives. The majority of breast cancers are invasive, which means that the cancer spreads and grows in healthy tissues. This is in comparison to noninvasive breast cancers which remain in the lobules or the milk ducts.

For triple-negative breast cancer (TNBC), the National Breast Cancer Foundation describes this particular cancer as the cells of the tumor that do not include the three most common forms of receptors, which is the HER-2 receptor, estrogen receptors, and progesterone receptors.

Investigators have been studying the potential use for decitabine in solid tumors, however the results are more encouraging than previous trials, exapalisn Cynthia Zahnow, PhD, an associate professor of oncology at the Johns Hopkins University School of Medicine. “We [researchers at Johns Hopkins] published a paper back in 2012 showing that these low doses of these drugs do have an effect in cancer tumors,” she explains, referencing a study published in March 2012 in the journal Cancer Cell.

The study suggested that the therapy could create an anti-tumor “memory” response, and inhibit growth of cancer stem-like cells. In the Mayo research study, the researchers used living xenografts (tissue from breast tumor cells). They found that decitabine can remarkably inhibit the growth of triple-negative breast cancers, however, the response was dependent on the presence of certain critical proteins known as DNA methyl transferase proteins (DNMT), which are present in a certain subset of triple-negative breast cancers.

“If researchers can truly select patients that have high levels of DNMT and show that these drugs are more effective in them, that’s a fantastic discovery,” notes Dr. Zahnow.

Sources: Journal of Clinical Investigation

About the Author
Master's (MA/MS/Other)
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
NOV 25, 2022
Clinical & Molecular DX
How a Multivalent Flu Vaccine Could Fight Against Future Pandemics
How a Multivalent Flu Vaccine Could Fight Against Future Pandemics
Scientists at the University of Pennsylvania have developed an experimental mRNA vaccine that protects against all known ...
DEC 21, 2022
Immunology
The Next Generation of Flow Cytometry Controls
The Next Generation of Flow Cytometry Controls
If you work in cell biology or immunology, chances are that you're familiar with flow cytometry. This technique meas ...
DEC 06, 2022
Drug Discovery & Development
The most expensive drug in the world, Hemgenix, approved at $3.5 million per dose
The most expensive drug in the world, Hemgenix, approved at $3.5 million per dose
On Tuesday, November 22nd, 2022, the United States Food and Drug Administration approved Hemgenix, a new drug to treat h ...
DEC 14, 2022
Drug Discovery & Development
The Two Brains Exposed by Ketamine
The Two Brains Exposed by Ketamine
Researchers out of the University of Pennsylvania have discovered our brains are split in two and not just along the hem ...
JAN 12, 2023
Drug Discovery & Development
Blood Pressure Drug Could Treat PTSD in Veterans
Blood Pressure Drug Could Treat PTSD in Veterans
A drug used to treat blood pressure and ADHD may be able to mitigate PTSD symptoms. The corresponding study was publishe ...
JAN 19, 2023
Drug Discovery & Development
Newest Treatment for Rosacea: Encapsulated Benzoyl Peroxide Cream
Newest Treatment for Rosacea: Encapsulated Benzoyl Peroxide Cream
Rosacea is a dermatologic condition affecting the centrofacial region (cheeks, chin, nose, and forehead), resulting ...
Loading Comments...